82-89-3
82-89-3 結(jié)構(gòu)式
基本信息
靈菌紅素
Aids010622
Aids-010622
PRODIGIOSIN
Prodigiosine
2-Methyl-3-amyl-6-methoxyprodigiosene
4-Methoxy-5-[(5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl], 2,2'bipyrrole
4-Methoxy-5-[(5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl]-2,2'-bi[1H-pyrrol]
4-Methoxy-5-(4-pentyl-5-methyl-2H-pyrrole-2-ylidenemethyl)-2,2'-bi[1H-pyrrole]
4-Methoxy-5-[(5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl]-2,2'-bi[1H-pyrrole]
物理化學(xué)性質(zhì)
常見(jiàn)問(wèn)題列表
Prodigiosin (25-500 nM; 24 hours) treatment reduces the viability of breast cancer cells, with IC
50
values at 48 h of 62.52 nM in MDA-MB-231 cells and 261.2 nM in MDA-MB-468 cells.
Prodigiosin (25-500 nM; 24 hours) treatment significantly reduces the levels of phosphorylated LRP6 and DVL2, active β-catenin, and total β-catenin. Prodigiosin noticeably inhibits the phosphorylation of GSK3β at Ser9 in HEK293T cells, which is indicative of an increase in GSK3β activity.
Prodigiosin can inhibit proliferation and induce apoptosis in breast cancer cells.
Prodigiosin (25-500 nM; 24 hours) treatment dose-dependently blocks Wnt signaling activated by Wnt1, Wnt3, Wnt1/LRP6, Wnt3/LRP6, and Dishevelled 2 (DVL2) in transfected HEK293T cells. Prodigiosin treatment inhibits Wnt3A-CM-induced transcription in a dose-dependent manner. Prodigiosin inhibits transcription of the SuperTopFlash reporter activated by either Wnt transfection or Wnt3A treatment.
When applied to cultures of chytrid fungi
Batrachochytrium dendrobatidis
and
B. salamandrivorans
, Prodigiosin causes significant growth inhibition, with MIC values of 10 μM and 50 μM, respectively.
Cell Proliferation Assay
| Cell Line: | MDA-MB-231 and MDA-MB-468 cells |
| Concentration: | 10 nM, 25 nM, 50 nM, 100 nM, 250 nM, 500 nM, 1000 nM, 2500 nM, 5000 nM |
| Incubation Time: | 24 hours, 48 hours |
| Result: | Reduced the viability of breast cancer cells, with IC 50 values at 48 h of 62.52 nM in MDA-MB-231 cells and 261.2 nM in MDA-MB-468 cells. |
Western Blot Analysis
| Cell Line: | HEK293T cells |
| Concentration: | 50 nM, 100 nM, 250 nM, 500 nM |
| Incubation Time: | 24 hours |
| Result: | Significantly reduced the levels of phosphorylated LRP6 and DVL2, active β-catenin, and total β-catenin. |
Prodigiosin (5 mg/kg; intraperitoneal injection; twice weekly; for 3 weeks) treatment significantly inhibits tumor growth. Prodigiosin treatment decreases tumor cell density and expression of the proliferation marker Ki-67.
| Animal Model: | Female BALB/c nude mice injected with MDA-MB-231 cells |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection; twice weekly; for 3 weeks |
| Result: | Significantly inhibited tumor growth in mice. |